1. .. , RGD: . ... . . . ., 2004. .. .
2005; 100(4- 5): 44-49. .., .. . . , . 2002; 4(2): 46-47. Allen N.E., Nicas T.l. Mechanism of action of oritavancin and related glycopeptide antibiotics. FEMS Microb. Rev. 2003; 26: 511-532. Aslam S., Hamill R.J., Musher D.M. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect. Dis. 2005; 5: 549-557. Baltch A.L., Smith R.P., Ritz W. et al. Comparison of Inhibitory and Bactericidal Activities and Postantibiotic Effects of LY333328 and Ampicillin Used Singly and in Combination against Vancomycin-Resistant Enterococcus faecium. Antimicrob. Agents Che- mother. 1998; 42: 2564-2568. Barcia-Macay M., Lemaire S., Mingeot- Leclercq M.P. et al. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 2006; 58: 1177-1184. Barriga C., Pedrera /., Rodruguez A.B.
Comparative study of the effect of teico- planin and vancomycin upon the phagocytic process of peritoneal macrophages. Rev. Esp. Fisiol. 1996; 52: 215-222. Biavasco F., Vignaroli C., Lupidi R. et al. In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide. Antimicrob. Agents Chemother. 1997; 41: 2165-2172. Billet S.E., Kortuem K.R., Gibson L.E., El- Azhary R. A morbilliform variant of vancomycin-induced linear IgA bullous dermatosis. Arch. Dermatol. 2008; 144: 774-778. Bleomycin: current status and new developments. Ed. by S.K. Carter. New York, 1978. Buttaro M.A., Pusso R., Piccaluga F. Vancomycin-supplemented impacted bone allografts in infected hip arthroplasty. Two-

stage revision results. J. Bone Joint Surg. Br. 2005; 87: 314-319. Caillon J., Juvin M.E., Pirault J.L., Drugeon
H.B. Bactericidal effect of daptomycin (LY 146032) compared with vancomycine and teicoplanin against gram-positive bacteria. Pathol. Biol. (Paris) 1989; 37: 540-548. Candiani G., Abbondi M., Borgonovi M. et al. In vitro and in vivo antibacterial activity of BI-397, a new semi-synthetic glycopeptide antibiotic. J. Antimicrob. Chemother. 1999; 44: 179-192. Centers for Disease Control. Nosocomial enterococci resistant to vancomycin. Morbid. Mortal. Wkly Rep. 1993; 45: 597-599. Elting L.S., Rubinstein E.B., Kurtin D. et al.
Mississippi mud in the 1990s: risks and outcomes of vancomycin-associated toxicity in general oncology practice. Cancer 1998; 83: 2597-2607. GanderS., Kinnaird A., Finch R.
Telavancin; in vitro activity against staphylococci in a biofilm model. J. Antimicrob. Chemother. 2005; 56: 337-343. Gerber J., Smirnov A., Wellner A. etal. Activity of LY333328 in experimental meningitis caused by Streptococcus pneumoniae strain susceptible to penicillin. Antimicrob. Agents Chemother. 2001; 45: 2169-2172. Giuliani A., Pirri G., Bozzi A. et al. Antimicrobial peptides: natural templates for synthetic membrane-active compounds. Cell Mol. Life Sci. 2008; 65: 2450-2460. Gold M.J., Calmon J., Wendeler M. et al. Synergistic bactericidal activity of rat serum with vancomycin against enterococci. J. Infect. Dis. 1991; 163: 1358-1361. Gonzalez-Ruiz A., Richardson J. Are glyco- peptides still appropriate and convenient for empiric use? J. Chemother. 2008; 20: 531-541. Hackbarth C.J., Lopez S., Trias J. et al. In vitro activity of the glycopeptide B1397 against Staphylococcus aureus and Staphylococcus epidermidis [abstract no 1283]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San-Francisco, 1999. Ishikawa H., Ito S., Nishio N. et al. Injection of bleomycin in newborn mice induces autoimmune sialitis that is transferred by CD4 T cells. Immunol. Cell Biol. 2009; 87: 351-358. Ishikawa H., Takeda K., Okamoto A. et al. Induction of autoimmunity in a bleomycin-induced murine model of experimental systemic sclerosis: an important role for CD4+ T cells. J. Invest. Dermatol. 2009; 129:1688-1695. Jauregui L.E., Babazadeh S., Seltzer E. et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice- daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin. Infect Dis. 2005; 41: 1407-1415. Jones R.N., Biedenbach D.J., Johnson D.M. et al. In vitro evaluation of BI-397, a novel glycopeptide antimicrobial agent. J. Chemother. 2001; 13: 244-254. Kaatz G.W., Seo S.M., Aeschlimann J.R. et al. Efficacy of LY333328 against experimental meticillin-resistant Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. 1998; 42: 981-983. Kamble R.T., Hamadani M., Selby G.B. Delayed myeloid engraftment due to vancomycin in allogeneic haematopoietic stem cell transplant recipients. J. Antimicrob. Chemother. 2006; 57: 795-796. Kasper M., Barth K. Bleomycin and its role in inducing apoptosis and senescence in lung cells modulating effects of caveolin-1. Curr. Cancer Drug Targets 2009; 9: 341-353. Kenney ., Tormey C.A. Acute vancomycin-dependent immune thrombocytopenia as an anamnestic response. Platelets 2008; 19: 379-383. Kirst H.A., Thompson D.G., Nicas T.l. Historical yearly usage of vancomycin. Antimicrob. Agents Chemother. 1998; 42: 1303-1304. Klinman D.M., Tross D. A single-dose combination therapy that both prevents and treats anthrax infection. Vaccine 2009; 27: 1811 1815. Kodama N., Yamada AL, Nanba H. Addition of Maitake D-fraction reduces the effective dosage of vancomycin for the treatment of Listeria-infected mice. Jpn. J. Pharmacol. 2001; 87: 327-332. Lacy M.K., Tessier P.R., Nicolau D.P. et al.
r
Comparison of vancomycin pharmacodynamics (1 g every 12 or 24 h) against methi- cillin-resistant staphylococci. Int. J. Antimicrob. Agents 2000; 15: 25-30.
Lamp .C., Rybak M.J., Bailey E.M., Kaafz W. In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin. Antimicrob. Agents Che- mother. 1992; 36: 2709-2714. Leblebicioglu H., Sencan I., Gunaydin M. ef al. Elution of vancomycin and tobramycin bonded to vascular grafts. J. Chemother. 1999; 11: 46-49. Lessard LA., Pratt S.D., McCafferty D.G. ef
al. Homologs of the vancomycin resistance D-Ala-D-Ala dipeptidase VanX in Strep- tomyces toyocaensis, Escherichia coli and Synechocystis: attributes of catalytic efficiency, stereoselectivity and regulation with implications for function. Chem. Biol. 1998; 5: 489-504. Lin G., Credito K., Ednie L.M. et al. Antistaphylococcal Activity of Dalbavancin, an Experimental Glycopeptide. Antimicrob. Agents Chemother. 2005; 49: 770-772. Machka K., Braveny I. Comparative in vitro activity of LY146032 (daptomycin) against gram-positive cocci. Eur. J. Clin. Microbiol. 1987; 6: 96-99. Marraffa J., Guharoy R., Duggan D. et al.
Vancomycin-induced thrombocytopenia: a case proven with rechallenge. Pharmacotherapy 2003; 23: 1195-1198. Meehl M., Herbert S., Gotz F., Cheung A. Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 2007; 51: 2679-2689. Mercier R.C., Houlihan H.H., Rybac M.L Pharmacodynamic evaluation of a new glycopeptide LY333328 and in vitro activity against Staphylococcus aureus and Enterococcus faecum. Antimicrob. Agents Chemother. 1997; 41: 1307-1312. Mohammadipour M., Mousivand M., Sale- hi Jouzani G., Abbasalizadeh S. Molecular and biochemical characterization of Iranian surfactin-producing Bacillus subtilis isolates and evaluation of their biocontrol potential against Aspergillus flavus and Colleto- trichum gloeosporioides. Can. J. Microbiol. 2009; 55: 395-404.
/" Moran F.J., Puente L.F., Perez-Giraldo C. et
al. Activity of vancomycin and teicoplanin against human polymorphonuclear leucocytes: a comparative study. J. Antimicrob. Chemother. 1991; 28: 415-418. Morimoto Y., Tatebayashi S., Imai Y., Kirita
T.  Efficacy of vancomycin-impregnated cement beads for the treatment of MRSA infection of failed graft tissue at the mandible.
J.  Oral Maxillofac. Surg. 2005; 63: 1234-1238. Mylonakis E., Ryan E.T., CalderwoodS.B. Clostridium difficileAssociated diarrhea: A review. Arch. Intern. Med. 2001; 161: 525-533. Neuner E.A., Ritchie D.J., Micek S.T. New antibiotics for healthcare-associated pneumonia. Semin. Respir. Crit. Care Med. 2009; 30: 92-101. PadialM.A., Barranco P., Lopez-Serrano C.
Erythema multiforme to vancomycin. Allergy 2000; 55: 1201. Pedrera M.I., Barriga C., Rodriguez A.B.
Intracellular activity of both teicoplanin and vancomycin against Staphylococcus aureus in human neutrophils. Comp. Immunol. Microbiol. Infect. Dis. 1995; 18: 123-128. Pedrera M.I., Perez F., Rodriguez A.B., Barriga C. Stimulation of phagocytosis against Staphylococcus aureus by teicoplanin and vancomycin. Rev. Esp. Fisiol. 1993; 49: 231-234. Raybak M.l. The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria. Clin. Microbiol. Infect. 2006; 12: 24-32. Rocha J.L., Hondo W., Baptista M.l. et al.
Uncommon vancomycin-induced side effects. Braz. J. Infect. Dis. 2002; 6: 196200. Rodruguez A.B., Ortega E., Barriga C. Uptake and intraphagocytic activity of teicoplanin in human neutrophils. Rev. Esp. Fisiol. 1993; 49: 163-167. Rodriguez A.B., Pedrera M.L, Barriga C.
In vivo effect of teicoplanin and vancomycin upon haemolytic and bactericidal activity of serum against Staphylococcus aureus. Comp. Immunol. Microbiol. Infect. Dis. 1996; 19: 283-288. Rotschafer J.C., Garrison M.W., Rodvold
K.  A. Therapeutic update on glycopeptide and lipopeptide antibiotics. Pharmacotherapy 1988; 8: 211-219.
Saleh-Mghir A., LefortA., Petegnief Y. etal.
Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis. Antimicrob. Agents Chemother. 1999; 43: 115-120. Segarra-Newnham M., Tagoff S.S. Probable vancomycin-induced neutropenia. Ann. Pharmacother. 2004; 38: 1855-1859. Selfzer E., Dorr M.B., Goldstein B.P. et al. Once-weekly dalbavancin versus standard- of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin. Infect. Dis. 2003; 37: 1298-1303. Snook M.E., Mitchell T., Hinton D.M., Bacon C.W. Isolation and Characterization of Leu(7)-Surfactin from the Endophytic Bacterium Bacillus mojavensis RRC 101, a Biocontrol Agent for Fusarium verticillioides. J. Agric. Food Chem. 2009; 57: 4287-4292. Stanley D., McGrath B.J., Lamp K.C., Rybak M.J. Effect of human serum on killing activity of vancomycin and teicoplanin against Staphylococcus aureus. Pharmacotherapy 1994; 14: 35-39. Streit J.M., Fritsche T.R., Sader H.S. et al.
Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn. Microbiol. Infect. Dis. 2004; 48: 137-143. Tawfik A.F. Effects of vancomycin, teicoplanin, daptomycin and coumermycin on normal immune capabilities. J. Chemother. 1991; 3: 226-231. Tsan P., Volpon L., Besson F., Lancelin J.M.
Structure and dynamics of surfactin studied by NMR in micellar media. J. Am. Chem. Soc. 2007; 129: 1968-1977. Van Bambeke F. Glycopeptides in clinical development: pharmacological profile andclinical perspectives. Curr. Opin. Pharmacol. 2004; 4: 471-478. Van Bambeke F., Van Laethem Y., Courva- lin P. et al. Glycopeptide antibiotics: from conventional molecules to new derivatives. Drugs 2004; 64: 913-936. Venditti M., Tarasi A., Capone A. et al. Teicoplanin in the treatment of enterococcal endocarditis: clinical and microbiological study. J. Antimicrob. Chemother. 1997; 40: 449-452. Wasilewski M.M., Disch D.P., McGill J.M. et al. Equivalence of shorter course therapy with oritavancin vs vancomycin/cephalex- in in complicated skin/skin structure infections [abstract no UL-18]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago (IL), 2001. Wood M.J. The comparative efficacy and safety of teicoplanin and vancomycin. J. Antimicrob. Chemother. 1996; 37: 209-222. Yamamoto T., Yokozeki H., Nishioka K. Fas- and FasL-deficient mice are resistant to the induction of bleomycin-induced scleroderma. Arch. Dermatol. Res. 2007; 298: 465-468. Zelenitsky S., Booker B., Karlowsky J. etal. Synergistic activity of an investigational [sic] glycopeptide, LY333328, and once-daily gentamicin against vancomycin-resistant Enterococcus faecium (VRE) in a multiple dose in vitro pharmacodynamic model. In Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington DC, 1997. Abstract F-9. Zheng M.H., Feng B., Li J.W. et al. Effects and possible anti-tumor immunity of electrochemotherapy with bleomycin on human colon cancer xenografts in nude mice. World J. Gastroenterol. 2005; 11: 2426-2430.



















<< | >>
: .. , .. , .. . 2012. 2012

:

- - - -
- - - - - - - - - - - - - -